The prognostic significance of MYC / BCL2 double expression in DLBCL in the genetic classification era
Cancer Science · 2025
DOI: 10.1111/cas.16377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yi-Fan Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Department of Science and Technology, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Double expression (DE) is a World Health Organization‐recognized adverse prognostic factor in diffuse large B‐cell lymphoma (DLBCL). However, the prognostic value of DE in the genetic subtyping era and potential mechanisms remain to be explored. We enrolled 246 DLBCL patients diagnosed between December 2021 and September 2023 in a Jiangsu Province Hospital cohort and included 930 DLBCL patients from three published studies in an external cohort. Double‐expression DLBCL (DEL) in the external cohort was mainly distributed in the OTHER subtype (42.0%), EZB subtype (28.3%), and MCD subtype (15.0%), whereas the MCD subtype exhibited the highest ratio of DEL. DEL was significantly related to unfavorable overall survival (OS) and progression‐free survival (PFS) in DLBCL, but only in EZB and OTHER subtypes that DEL retained remarkably adverse impacts on survivals compared to non‐DEL. We explored the prognostic value of clinical and genetic parameters in DEL patients and found only ST2 showed better OS than A53 in DEL patients, whereas the other subtypes showed no significant difference. DEL showed similarities with the MCD subtype in mutation profiles. Furthermore, RNA‐sequencing analyses exhibited upregulation in tumor proliferation‐related pathways in DEL patients, but downregulation in extracellular matrix organization, T‐cell activation and proliferation, type II interferon production, and pathways associated with cell death might contribute to the poor outcomes of DEL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
- Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
ORCID-Profile: Wei Xu
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Department of Science and Technology
- China Postdoctoral Science Foundation
Zitieren
APA
Wu, Y. F., Yuan, Q. H., Shen, H. R., Du, K. X., Shang, C. Y., Li, Y., Zhang, X. Y., Wu, J. Z., Gao, R., Wang, L., Li, J. Y., Yin, H., Liang, J. H., & Xu, W. (2025). The prognostic significance of MYC / BCL2 double expression in DLBCL in the genetic classification era. Cancer Science. https://doi.org/10.1111/cas.16377
Vancouver
Wu YF, Yuan QH, Shen HR, Du KX, Shang CY, Li Y, et al. The prognostic significance of MYC / BCL2 double expression in DLBCL in the genetic classification era. Cancer Science. 2025. doi:10.1111/cas.16377
BibTeX
@article{Wu2025,
author = {Wu, Yi-Fan and Yuan, Qun-Hui and Shen, Hao-Rui and Du, Kai-Xin and Shang, Chun-Yu and Li, Yue and Zhang, Xin-Yu and Wu, Jia-Zhu and Gao, Rui and Wang, Li and Li, Jian-Yong and Yin, Hua and Liang, Jin-Hua and Xu, Wei},
title = {The prognostic significance of MYC / BCL2 double expression in DLBCL in the genetic classification era},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16377}
}
EUVIMED